ロード中...
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma
Non-small cell lung cancer (NSCLC) patients with c-MET dysregulation may benefit from c-MET inhibitors therapy as inhibition of c-MET activity has emerged as a therapeutic approach against this disease. Although several c-MET inhibitors have been evaluated in multiple clinical trials in lung cancer,...
保存先:
| 出版年: | Am J Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
e-Century Publishing Corporation
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7061748/ https://ncbi.nlm.nih.gov/pubmed/32195027 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|